NCCN Guidelines(R) Recommend VONJO(TM) (pacritinib) for the Treatment of Myeloproliferative Neoplasms

VONJO is the only approved JAK inhibitor recommended by NCCN for myelofibrosis patients regardless of platelet count SEATTLE, April 14, 2022 -- (Healthcare Sales & Marketing Network) -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced that VONJO™ (pa... Biopharmaceuticals, Oncology CTI BioPharma, VONJO , pacritinib, Myeloproliferative Neoplasms, JAK inhibitor
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news